Exclusive Summary

• **First-in-Class Innovation & Delivery**: UB439 is a stress-adaptive protein therapy utilizing a **Nasal Spray formulation** (UBD002 series), significantly enhancing compliance for comprehensive pediatric ASD treatment compared to injectables.
• **Disease-Modifying Mechanism**: Unlike symptomatic treatments, it targets neuroinflammation (NF-κB pathway) and multi-target neural network repair, aiming to address the underlying pathology of autism.
• **Clinical Readiness**: UB439 has obtained **Ethical Approval for Investigator-Initiated Trials (IIT)**, positioning it for rapid generation of human proof-of-concept data.
• **Scalable Manufacturing**: Leveraging a standardized "cell-free, non-exosomal" platform with high batch consistency (Pearson > 0.94), it overcomes the scalability and stability bottlenecks typical of biologic therapies.

Asset Materials

Contact Us for Full Materials